Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study published online July 15 in the Journal of Allergy ...

Introduction Benralizumab and mepolizumab are subcutaneous monoclonal antibodies licensed for the treatment of severe eosinophilic asthma. Benralizumab acts by blocking the anti-IL5 α receptor whilst ...